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Abstract: Although it is known that agglutinins specific for bromelin-treated red 
blood cel1 (BrRBC) exist in normal human serum， their immunological and biological 
characteristics have not yet been elucidated. We have found two different types of 
agglutinins specific for BrRBC in the normalserum. The one reacts specifical1y with red 
blood cel1 (RBC) pretreated for 15 minutes with lower concentration of bromelin (Br) (1. 25 
U/ml to 25 U/ml in terms of casein-digestion activity)， and thus， itis responsible for the 
non-specific agglutination encountered in routine works. The other is detected with RBC 
pretreated with Br of higher activities (> 125 U/mI). The former agglutinin was proved to 
be IgM and the laUer to be IgG on the basis of biochemical and immunological criteria， and 
they are termed NSA-BrRBC-1 (non-specific agglutinin for BrRBC) and NSA-BrRBC-I， 
respectively. The incidences of NSA-BrRBC-1 and -I in normal human sera were 2.3 % 
and 99.9 %， respectively. The binding site for NSA-BrRBC-1 on RBC was specifical1y 
elicited by mild Br-treatment but not by other proteinase digestions. From the Br-digestion 
products of RBC membrane， we partially purified the protein fraction which exhibited a 
high inhibitory activity against the agglutination by NSA-BrRBC-1 without suppressing 
the agglutination by most of the blood group antibodies examined. This fraction was 
therefore assumed to contain the target protein of NSA-BrRBC-1. Four fragments with 
different molecular weights (26，000， 61，000， 74，000 and 160，000 dalton) could be detected 
by Western blotting of the fractions after immunoprecipitation and electrophoresis in the 
reduced condition. This fraction successful1y inhibited non-specific agglutination by NSA 
BrRBC-1 in two-stage Br-method but not in one-stage method. 
These results indicate that one of the non-specific agglutinations of BrRBC encountered 
in routine works is caused by the interaction between NSA-BrRBC-1 and Br-modified 
membrane protein(s) 
Index Terms 
non-specific agglutination， bromelin treated red blood cel1， immunoglobulin， membrane 
protein 
INTRODUCTION 
It is known that red blood cel1s (RBCs) treated with proteinases are often agglutinated with 
normal sera independently of the blood groups of the donorsl-6). Such a so-cal1ed non-specific 
(NS) agglutination is often encountered in the enzyme digestion process for screening and 
identifying antibodies in the donor and patient sera or the crossmatching test for the blood 
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transfusion. 
The enzyme methods are highly sensitive for detecting several antibodies， especially Rh 
antibodies7-10). Although the exact mechanism of enhanced sensitivity in these methods are not 
clear， itis conceivable that the removal of sialopeptides from RBC surface by proteinases 
would contribute to this enhancement. Two enzyme methods， one-stage and two-stage， are 
commonly used in the routine tests in clinicallaboratories. The former is technically simpler 
and more quick and the latter is more sensitivell). Sulfidryl-proteinases with broad specifity 
such as bromelin CBr)， papain CPa) and ficin CFi) are frequently used in the enzyme methods. 
Br is suita.ble for both one-stage and two-stage methods and the NS-agglutination can be 
detected by these two methods. 
The presence of an agglutinin specific for trypsin CTr)-treated RBC in normal human serum 
is well known2). This agglutinin is of IgM type， and its epitope has been suggested to be a 
glycoprotein present on RBC surface12). The presence of NS-agglutinins specific for other 
proteinase-treated RBCs has also been reported in normal serum3). Several workers5)6) report】
ed the presence of agglutinins specific for Br-treated RBC CBrRBC) in the serum and the 
destruction of their agglutinabilities by 2-mercaptoethanol. However， immunological and 
biochemical properties of the agglutinins and the precise mechanism of NS-agglutination in 
Br-methods are at present stil unclear. 
In the present study， we analyzed the NS-agglutinations in the Br-methods and found that 
these agglutinations were composed of two phases ; one is exerted by IgM -type agglutinin and 
the other by IgG-type one. We also discovered that the reactivities of these agglutinins depend 
on the degree of RBC surface modification by Br. In addition， a protein fraction which was 
thought to contain the target of IgM-type agglutinin was obtained from BrRBC membrane. 
The molecular properties of the target proteinCs) are characterized to some extent. A possible 
mechanism of NS-agglutination by IgM -type agglutinin is discussed on the basis of the reaction 
of this agglutinin with its target proteinCs). 
MATERIALS AND METHODS 
Blood samρles and blood group antibodies. All RBCs used in this study were obtained from 
blood group 0 donors. Sera containing NS-agglutinin were from blood donors whose sera 
showed NS-agglutination in routine tests. Monoclonal anti-glycophorine A CGPA) antibodies 
Canti-EnaTS， anti-EnaFS and anti-EnaFR) 13) were obtained from Osaka Red Cross Blood 
Center. Other blood group antibodies were purchased from commercial sources. 
Preρaration 01 enzyme solutions. Br， Tr， Pa and Fi were purchased from E. Merck 
CDarmstadt， Germany). Br， Tr， Pa and Fi solutions were prepared according to the method as 
previously described14). Proteinase K CPrK) CBoehringer Mannheim GmbH， Biochemica， 
Mannheim， Germany) was dissolved at 1 mg/ml in 50 mM  Tris buffer CpH 8.0) CTB) contain-
ing 1 mM  CaC12・ Brsolution was freshly prepared in each experiment whi1e the other 
proteinase solutions were stored below -20"C until use. 
Proteinase activity was determined by casein-digestion method CHagihara et aP5)). One u日it
of proteinase activity was defined as the activity giving an increase of absorbance at 275 nm 
which is equivalent to 1μg tyrosine liberation per minute. 
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Serological tests. Agglutination tests， measurement of agglutination titer and dithiothreitol 
(DTT) treatment of sample serum or sample solution were performed according to the AABB 
technical manuaj16). The two-stage method was usually used for agglutination tests throughout 
this study except as otherwise indicated. 
The strength of agglutination was expressed in five steps (-to 4+) according to the inter. 
pretation of agglutination in the AABB technical manuaj16). 
Absorption test of NS-agglutinin was performed as follows: RBCs were pretreated with 
0.125 % Br (HBrRBC) or 0.0025 % Br (LBrRBC) at 3TC for 15 minutes. Serum or sample 
solution was added to an equal volume of packed HBrRBC or LBrRBC and mixed well. After 
standing at room temperature for one hour， the supernatant solution obtained by centrifugation 
was used for agglutination test. 
Sゆaration0/ agglutinin. Serurn proteins in the pooled plasma with high agglutinability 
specific for BrRBC were fractionated by sedimentation with ammonium sulfate between 20 % 
and 50 % saturation. The obtained precipitate was dissolved in PBS ilnd dialyzed against 20 
mM  TB at 40C. After centrifugation of the dialysate， the obtained supernatant solution was 
applied to a Q-Sepharose FF (Pharmacia LKB Biotechnology， Upssala， Sweden) column 
(2.6 x 40 cm) equilibrated with 20 mM  TB. The column was washed with 300 ml of 20 mM  TB 
and subsequently eluted stepwise with solution of 0.1， 0.16， 0.23， 0.3 and 0.5 M N aCl in 20 mM  
TB each for 200 or 300 ml. Proteins in effluent were monitored by the absorbance at 280 nm， 
and the presence of agglutinin activity in the fractions was examined both with HBrRBC and 
LBrRBC. 
Fractions containing higher agglutination activity with HBrRBC or LBrRBC were concen. 
trated and applied to a Sephacryl S-300 (Pharmacia) column (2.3 x 93 cm) previously equili. 
brated with 0.1 M TB containing 0.5 M N aCl. The elution was performed with the same 
buffer. 
Absorption 0/ agglutinins by immunoglobulin-class specific affinity gel. 
1) Absorption of IgM-type agglutinin: Rabbit anti-human IgM (Dakopatts， Glostrup， 
Denmark) was conjugated with Afigel-10 (Bio-Rad， Richmond， CA， USA) according to the 
instruction manual. Sample serum was mixed with the anti-human IgM-conjugated agarose 
(2.7 mg protein/ml geI) and incubated at room temperature for 3 hours. After the agarose was 
washed with PBS， itwas incubated with 3 M KSCN and stood for 30 minu 
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Then， the BrRBCs were washed three times with cold saline and incubated with 100μ1 of 
fluorescein isothiocyanate (FITC)-conjugated anti-human IgM or anti-human IgG (diluted 1 : 
7 with 5% BSA in PBS) (Behringwerke AG， Marburg， Germany). The labeled BrRBCs were 
again washed with cold saline and the fluorescent images of the BrRBC were observed under 
a fluorescence microscope. 
ElectroPhoretic procedures. Immunoelectrophoresis was performed according to the method 
described by Garbar et aP7). Sodiumdodecyl sulfate-polyacrylamide gel electrophoresis CSDS-
P AGE) was carried out according to Fairbanks et aPS) using a 5.6 % or 8 % polyacrylamide 
slab gel with 1 mm thickness. Proteins were detected with Silver Stain Plus Kit (Bio-Rad). 
Western blotting was carried out by electrophoretic transfer of proteins from the SDS-P AGE 
gel to Immobilon P transfer membrane (乱I[illipore，Bedford， MA， USA). The protein blots of 
NS-agglutinins on the membrane were detected with horseradish peroxidase CHRP)一conjugat同
ed anti-human IgM and anti-human IgG CCappel， urganon Teknika Co.， West Chester， PA， 
USA). For the analysis of the target protein(s) of NS-agglutinin， partially purified NS 
agglutinin and anti-GPAs were used as primary antibodies. Protein blots reactive with these 
reagents were visualized by streptavidin biotinylated HRP complex CAmersham， Amersham， 
UK) or streptavidin-alkaline phosphatase (ALP) conjugate CAmersham) using biotinylated 
anti -human IgM CAmersham) or biotinylated anti -mouse immunoglobulin (Dakopatts) as 
secondary antibodies. 4-Chloro-1-naphtol， and nitroblue tetrazolium and 5-bromo-4-chloro-3-
indolyl phosphate were used as color-developing reagents for HRP and ALP， respectively. 
Isolation 01 the targetρrotein(s) 01 NS-agglutinin jヤ'OmBrRBC. The activity of the target 
protein of NS-agglutinin was defined as the reciprocal of the highest dilution of samples to 
inhibit the reaction of LBr RBC with NS-agglutinin. The inhibitory activity of a sample 
solution against the agglutinin was measured as follows : Serial twofold dilutions of a sample 
were prepared with PBS containing 5% BSA. To each series of diluted samples， an equal 
volume of diluted agglutinin solution with 8-fold agglutination titer was added and mixed well. 
After standing for 30 minutes， a half volume of 2% LBrRBC suspension was added to each 
mixture. The detection of agglut 
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with TBA. After washing the column with TBA and TBA containing 0.15 M N aCl， active 
fractions were eluted with a linear gradient of N aCl in TBA up to 0.4 M. The obtained 
fractions were rechromatographed by the elution with a linear gradient of N aCl from 0.25 to 
0.5 M. The active fractions eluted were collected and concentrated by ultrafiltration as 
described above after Bio-Beads SM-2 treatment. 
Protein concentration was determined with Bio-Rad Protein Assay (Bio-Rad) and Micro 
BCA Protein Assay Reagent Kit (Pierce， Rockford， IL， USA). 
lmmunoprecipitation 01 targetρrotein. The partially purified NS-agglutinin with IgM 
properties was conjugated to Afigel-10 (850μg protein/100μ1 ge1). After washing three times 
with a sufficient volume of the coupling buffer containing 0.05 % Amphitol 20 N， the conjugaι 
ed gel was suspended in an equal volume of 50 mM  TB containing 0.05 % Amphitol 20 N and 
0.15 M N aCl (TBAS). The pH of the final1y obtained solution containing target protein (1.1 
mg/ml，300μ1) was adjusted to 8.3 with 50μ1 of 0.5 M sodium bicarbonate buffer (pH 8.3). 
To this solution， 50μ1 PBS containing NHS-LC-Biotin (Pierce) (1 mg/m1) was added and 
after standing for 2 hours at 4'C， the solution was applied to a Sephadex G-25 mini-column 
equilibrated with 50 mM  TBAS to remove unreacted biotin and change the buffer solution. The 
eluted biotinylated protein fraction was concentrated to 200μ1 by ultrafiltration and added into 
the micro centrifuge tube containing 100μ1 of the agglutinin-conjugated Afigel-10 suspension. 
After 2 hours of incubation on a rotary mixer at room temperature， the gel was washed three 
times with 50 mM  TBAS and once with 5 mM  TB and then mixed with 100μ1 of the sa1nple 
buffer for SDS-PAGE containing 2-mercaptoethanol. After heating at 100'C for 5 minutes， the 
supernatant solution was applied to SDS-PAGE. Procedures for SDS-PAGE and Western 
blotting were the same as described above. The biotinylated proteins on the blotting membrane 
were detected by incubating with streptavidin biotinylated HRP complex (Amersham) diluted 
to 1 : 5，000 for an hour at room temperature followed by chemiluminescence detection (ECL 
Western blotting detection reagents ; Amersham). The membrane was exposed to autoradio同
graphy film (Hyperfilm-ECL ; Amersham) for 2 hours. The proteins transferred to the blotting 
membrane were stained with 0.1 % amido black 10 B in 45 % methanol and 10 % acetic aCld 
RESULTS 
Theρresence 01 two d坊'erentand sequential NS-agglutinations 01 BrRBC in normal serum. 
The NS-agglutinability of normal serum was examined vvith RBC premodified by different 
concentrations of Br. As shown in Fig. 1， the NS-agglutination of BrRBC consists of two 
phases : One is observed by the 15-minute pre-modification of RBC with Br of activity between 
1.25 U/ml and 25 U/ml (LBrRBC) and the other is seen above 125 U/ml (HBrRBC). These 
two types of NS-agglutination were assumed to be caused by the presence of at least two 
different agglutinins in the normal sera， because the agglutination of LBrRBC was diminished 
by the preincubation of serum with LBrRBC but not with HBrRBC and vice versa 
To substantiate the above assumption， NS-agglutinability of the serum was further analyzed 
by changing both Br concentration and duration time of Br-treatment. As shown in Table 1， 
NS-agglutinability was completely separated into two distinct activity areas on the 2-dimen田
sional matrix composed of these two parameters. Thus， the results indicate the presence of two 
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Fig. 1. Agglutination of RBCs treated with increasing concentration of Br by 
the serum with NS-agglutinins. Intensity of agglutination is express 
ed as the r巴ciprocalof the high巴stdilution of the s巴rumwhich gives 
detectabl巴 agglutination
types of NS-agglutination which depends on the degree of modification of RBC by Br， i. e.， one 
is induced by mildly Br-modified RBC and the other by drastically modified RBC. Treatment 
with 0圃 0025% Br for 5 seconds was the mildest condition for obtaining LBrRBCs. In such a 
mild condition， MN  antigens on RBCs stil remained intact， though Br removes MN antigens 
from RBC surfaces in the normal condition of pretreatment. The maximum extent of Br 
treatment for mildly modified RBC was attained at a value slightly lower than 1，000 U・min/
ml， which is expressed as the product of the effective Br activity CU/ml) and the incubation 
time Cminute). On the other hand， the minimum extent for drastically modified RBC was 
slightly higher than 1，000 U emin/ml. Thus， these results indicate that two physically distinct 
entities are involved in these two types of agglutination. 
Hereafter， NS-agglutinins for mildly modified RBC and drastically modified RBC are 
defined as NSA-BrRBC-1 and NSA-BrRBC-I CNS-agglutinin 1 and I for BrRBC). 
Separation and Characferization 01 twoかtes01 NS-agglutinins. To clarify the molecular 
properties of NS-agglutinins， an attempt to separate NS-agglutinins from sera was made. 
Both activities of NSA-BrRBC-1 and -I were successfully collected in a fraction obtained 
from a pooled serum with NS-agglutinability by sedimentation with ammonium sulfate. From 
this fraction， five fractions CPT， 1， I， IIand IV) having NS-agglutinability for BrRBC were 
separated by Q-Sepharose ion-exchange chromatography CFig. 2). Fractions PT and 1 
contained NSA-BrRBC-I while fractions II and IV exhibited the activity of NSA-BrRBC-1 . 
Fractions 1 and IV with peak activities of NSA-BrRBC-I and -1 ， respectively， were further 
purified by gel filtration CFig. 3). The activity of NSA-BrRBC-I was finally recovered in 
fraction 1 -2 whereas NSA-BrRBC-1 was found in fraction IV-2. Since the elution positions 
of the NSA -Br RBC-1 and -I fractions on the chromatographies used in the purification 
corresponded with those of IgM and IgG， respectively， each immunoglobulin type of NSA 
BrRBC-1 and -I was assumed to be IgM and IgG. This assumption was supported by the 
results of DTT treatment， immunoelectrophoresis， SDS-P AGE， Western blotting and immuno一
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Fig. 2. Q-Sepharose ion-exchange chromatography of serum prot巴ins.Serum proteins in the pooled human 
plasma with NS-agglutinability were fractionated by sedimentation with ammonium sulfat巴， dialized 
and subjected to Q-Sepharose ion-exchange chromatography as described in "MATERIALS AND 
METHODS". Elution was first carried out with 20 mM TB， and then by st巴pwis巴mcr巴aseof NaCl 
up to 0.5 M， ata flow rate of 150 ml/hr. Column size was 2.6 x 40 cm. Agglutination activity in th巴
fractions was expressed as th巴 intensityof agglutination. 
， absorbance at 280 nm;一一一一一， concentration of NaCl;匡霊童盟， agglutination activity with 





detection with these fractions. In addition， NSA-BrRBC-1 was found to be specifically 
absorbed with anti-human IgM-conjugated agarose while NSA-BrRBC-I with Protein G 
agarose， and they were eluted from each absorbent by the corresponding elution reagents. 
Furthermore， BrRBCs which were agglutinable by NSA-BrRBC-I were found to be stained 
specifically with FITC-conjugated anti-IgG but not with anti-IgM， while those by NSA 
BrRBC-1 were fluoresced only with anti-IgM CFig. 4). These results are summarized in Table 
2. 
When sera without alloantibodies from 1，000 normal donors were examined， the incidences 
of the presence of NSA -Br RBC-1 and -I in these sera were 2.3 % and 99.9 %， respectively. 
Effecお 0/treatment with other ρroteinases 0η the reacfivity 0/ NSA -BrRBC -1. The 
agglutinability of NSA-BrRBC-1 for RBCs treated by various proteinases was investigated. 
When RBCs were treated with several proteinases CTr， Pa， Fi and PrK) other than Br for 
different periods of time， they could not be agglutinated by NSA -BrRBC-1 even though their 
MN  antigens stil remained to be expressed. 
To investigate whether the binding site of NSA-BrRBC-1 is susceptible to these 
proteinases， treatment with these proteinases was carried out before and after Br-treatment 
CTable 3). The agglutination by NSA-BrRBC-1 was positive with RBC treated with Tr or 
PrK before or after Br-treatment. On the other hand， RBC treated with Pa or Fi before and 

























































E 1 u t i 0 n Vo 1 ume (m 1) 
Fig. 3. Gel filtration of the agglutinins. Proteins in the fractions 1 and IV obtain巴din Q-Sepharose st巴p(Fig 
1) were collected by sedimentation with ammonium sulfate and subjected to gel filtration through a 
Sephacryl S-300 column as described in "MATERIALS AND METHODS'¥Elution was carried out 
with 0.1 M TB containing 0.5 M N aCl at a f10w rate of 48 m1/hr. Column size was 2.3 x 93 cm 
Agglutinin activity in the fractions was巴xpress巴das th巴intensityof agglutination. A; elution profile 
of fraction 1. B; elution profile of fraction IV 






Isolation 0/ targetρrotein (s) 0/ BrNSA -1. Since the preceding results suggest that the 
target of NSA-BrRBC-1 is membrane protein， we tried to isolate the relevant membrane 
protein(s) from BrRBC ghost on the assumption that the target protein might exhibit an 
inhibitory activity against NSA-BrRBC-1 agglutination. In fact， such an activity could be 
detected in a crude membrane extract of BrRBC， and as shown in Fig. 5 A， the gel filtration of 
the extract gave two large protein peaks and the inhibitory activity was detected in the second 
peak (Fig. 5 A). The membrane extracts from RBC without Br-digestion and any fractions of 
this extract eluted by gel filtration did not show inhibitory activity (Fig. 5 B). 
An anion-exchange chromatography of the obtained fraction separated a peak of the inhibi. 
tory activity (Fig. 6 A). The main fractions exhibiting the activity were rechromatographed 
(Fig.6 B) and the resultant active fractions were combined and termed NSA-BrRBC-1 -RP 
(receptor protein for NSA-BrRBC-1 )， and were used for further experiments. The final yield 
of protein in this fraction was 2.4 mg from 100 ml of packed RBC. The final specific activity 
of this fraction was 80-fold higher than that of the initial extract (Table 4). A marked 
reduction of the inhibitory activity of the RP found at the gel filtration step seems to be due 
to the presence of Triton X -100 remaining in this fraction， because the activity of the RP was 
N on-specific agglutination of bromelin-treated red blood cells (401) 
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Fig. 4. Immuno-fluorescent staining of HBrPBC (A -D) and LBrRBC (E-H) by NS-agglutinins of 
IgG and IgM type， r巴spectively. Both HBrRBC and LBrRBC were stained with FITC 
conjugated anti-human IgG (A and E) and anti-human IgM (C and G). B， D， F and H are 
th巴 lightmicroscopic photographs of the agglutinated BrRBCs corresponding to A， C， E and 
G， resp巴ctively.
Table 2. Charact巴risticsof non -sp巴cificagglutinins for BrRBC 
Item 
Incidence in N ormal Serum (%) 





Sensitivity to DTT 
Behavior in Immunoelectrophoresis 
Adsorption with 
Anti -IgM -ConjugatedAgarose 
Protein G Agarose 
Molecular weight 
Analyzed by SDS-PAGE 

















Very Larget 150K， 180K， 300K 





Procedures of al the investigations cited in this Table were described in "MA TERIALS AND 
METHODS" 
ネ Th巴rangeof Br activity required to induce NS-agglutination of RBC for 15-minute incubation. 
↑The band detected on the gel or membrane showed very slow migration rate. 
Abbreviation: LBrRBC， RBC treated with low-active Br; HBrRBC， RBC treated.with high-active Br; N 
T.， not tested. 























































Fig. 5. Gel filtration of the extract from RBC ghost. Each of the巴xtractfrom 
LBrRBC ghost (A) and unmodified RBC ghost (B) was treated with Bio 
Beads SM-2， concentrated by ultrafiltration and subjected to gel filtration 
through Sephacryl S-300 column as described in "MA TERIALS AND 
METHODS'¥Inhibitory activites against NSA-BrRBC-1 in efflu巴ntswere 
expr巴ssedas the reciprocal of the highest dilution of samples to inhibit the 
agglutination of LBrRBC with NSA-BrRBC-1. Elution was carried out with 
50 m M  TBA containing 0.5 M N aCl at an巴lutionrate of 37.2 ml/hr (A) or 
41. 9 ml/hr (B)目 Columnsizes wer巴 2.2XIOOcm(A) and 1.6X40cm (B). 







Table 3. Susceptibility of the binding sites of NSA-BrRBC-1 on RBCs to various Proteinases 
Proteinase treatment 
Pa Fi Tr PrK Br Br Br 
↓↓↓ ↓↓↓↓  
BBr  Br Br Pa Fi Tr 
士 2十1+土2+
RBCs wer巴 incubatedwith proteinase at 37 "C for 15 minutes and， after washing 3 times with saline， were 
subjected to agglutination tests as described in "MA TERIALS AND METHODS". The proteinase 
activities used in RBC treatments were approximately 10 U/ml for Br， Pa and Fi and 80 U/ml for PrK. The 
arrow (↓) indicates the order of proteinase-treatments of RBC from 1st treatment to 2nd treatment. The 
strength of the agglutination was e況pressedas in Table 1 
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Fig. 6. Q-Sepharos巴ion-exhcangechromatography of the target protein(s) of NSA 
BrRBC-I. The obtain巴dfractions with inhibitory activity against NSA-
BrRBC-I in the previous gel filtration (Fig. 5A) w巴recombined， dialized 
against 20 mM  TBA and subj巴ctedto Q-Sepharose ion-exchange chromato. 
graphy as d巴scribedin "MATERIALS AND METHODS". Elution was first 
carried out with.20 m M  TBA， and then by a gradient of NaCl at a rate of 102 
ml/hr. Column size was 1. 6 x 20 cm. 
A: The initial chromatography. B: Th巴 r巴chromatographyof the fraction 
mark巴dwith the bar in A 
一一一一， absorbance at 280 nm ; 一一一， concentration of N aCl ;←@←-， inhibi-
tory activity against NSA-BrRBC-1. 
300 200 100 
O 
Table 4. Summary of purification of NSA-BrRBC-I -RP 
Total Protein Total Recovery of Specific 
Protein Recovery Activity Activity Activity 
(rng) (%)αold) (%) (fold九ng)
[A] [B] [B/ A] 
Extract 88.0 100 64.000 100 727 
G巴1Filtration 17.2 20 2，560 4 149 
Ion-Exchange Chrornatography 2.4 3 140.000 220 58，182 
RP activity was defined as the highest rate of dilution of the preparation by which the hernagglutinating 
activity of NSA-BrRBC-1 with 4 fold titer was cornpletely inhibited. 
Isolation Step 
(frorn 100 ml RBC) 
restored or rather increased after complete removal of Triton X -100 by subsequent ion-
exchange chromatography. 
SDS-PAGE and vf，う~stern blotting 01 the ραrtialyρur:折:edNSA-BrRBC-1 -RP. To examine 
the purity of the obtained NSA-BrRBC-1 -RP fraction， SDS-PAGE analysis was performed. 
It revealed two major and several minor bands by silver staining (Fig. 7 A). 
Since the molecular size of RP could not be estimated by SDS-P AGE， we tried to analyze it 
















Fig. 7. SDS-PAGE (A) and Western blotting (B) of th巴targ巴tprot巴in
。fNSA-BrRBC-1 (NSA-BrRBC-1 -RP). NSA-BrRBC 
1 -RP fraction finally obtained from the extract of LBrRBC 
ghost in the ion-exchange chromatography (Fig. 6B) was 
subjected to SDS-P AGE and Western blotting， SDS-PAGE was 
performed according to Fairbanks et al18). Prot巴insin the g巴1
w巴r巴 detectedby a silver staining method. Western blotting 
was performed by the m巴thodas d巴scribedin d巴tailin 
"MATERIALS AND METHODS". The RPs w巴rebiotinylated， 
conc巴ntrat巴dby immunopr巴cipitationand subj巴ctedto SDS-
PAGE. Aft巴rtransferring the biotinylated RPs from the gel 
onto blotting membrane， the blots of RPs were detected by the 
chemil uminesc巴nce detection m巴thod using streptavidin 
biotinylat巴dHRP complex. The mark巴rproteins on the mem 
brane were stained with amidoblack 10B. Lanes 1 and 3 ; the 
partially purified NSA-BrRBC-1 -RP. Lanes 2 and 4; molecu-
lar weight marker. 
biotinylated RP obtained from the membrane extract by immunoprecipitatiort showed a main 
band with the molecular weight of 74，000 dalton and three minor bands with the molecular 
weights of 26，000， 61，000 and 160，000 dalton CFig. 7 B). 
N 0 significant band was detected from the partially purified RP by Western blotting using 
anti-GPAs as primary antibodies or by immunoprecipitation using them as ligands. 
Specijiciかαndapplicability 01 NSA-BrRBC-1 -RP to inhibit NS-agglutinatioη. To confirm 
that the inhibitory activity of NSA-BrRBC-1 -RP is specific to the agglutination of BrRBC 
with NSA-BrRBC-1， we examined whether NSA-BrRBC-1 -RP inhibits the agglutination of 
RBC with various blood group antibodies CTable 5). The RP weakly inhibited the agglutination 
with anti-U， but its inhibitory activity was below 1/1，000 of that for NSA-BrRBC-1. The 
agglutination with other antibodies examined so far in this study was not inhibited by NSA-
BrRBC-1 -RP. 
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Tabl巴 5.Inhibitory effects of the partially purified NSA-BrRBC-I -RP on agglutination of RBC by blood 
group antibodi巴s


























Each agglutination of RBC by antibodies cit巴din th巴 Tabl日wasinvestigated in the optimum conditions as 
described in the instruction manuals 
キ， t Lectin. 
目Inhibitiontiter was 4. 
， Inhibition titer was above 5， 120 
Table 6. Inhibitory effects of the partially purified NSA-BrRBC-I -RP on non-specific agglutination with 
NSA-BrRBC-I in two different Br-methods 
Two-stage Method On巴 stageMethod 
Serum Addition 
Incubation Time of RP with Serum Incubation Tim巴ofRP with Serum 
No. of RP 
5min. 15min. 30min目 60min. 5min. 15min. 30min 60min 
寸一 2十 3十 3十 3+ 
3十 3-c- 3+ 3十 2+ 3+ 3+ 3十
2* 
+ 3十 3+ 2十 2+ 4十 4十 3十 3十
3十 4-'- 4十 3十 4+ 4十 3十 3+ 
3 
十 土 3+ 3+ 3+ 3十
3十 4 3十 3十 3十 3+ 3十 3+ 
4 
十 + 十 + + 3+ 3+ 3十 3+ 
3十 3十 3+ 3+ 3十 3十 3+ 3+ 
十 3十W 3十W 3十w 3+w 
5 
3十w 3十W 3+w 3十 3+w 3+w 3十w 3十W
6 
+ 1+ 1十 1+ 1十
2十 2十 l十S 2十 1十 1+ 1十 1+ 
Sera containing NSA-BrRBC-1 with agglutinin titer of 32 to 128 w巴rediluted four times with AB serum 
without NSA-BrRBC-1. The partially purified NSA-BrRBC-1 -RP with inhibition titer of 1， 024 was 
diluted 20 times with the same AB serum as above. An equal volume of these dilut巴dserum and RP was 
mixed and incubated at room temperature for the indicated times. After the incubation， the samples were 
subjected to the two Br-methods as described in the t巴xt.
* This serum contained anti-1 . 
In order to examine the applicability of NSA-BrRBC-1 -RP in routine works， the ability of 
the RP to inhibit NS-agglutination was tested by using several sera with different NS-aggluti-
nation activities (Table 6). In the two-stage method， the RP successfully suprressed the 
agglutinability of all the sera with different activity levels of NSA -Br RBC-1 by pre-incuba-
tion for over 30 minutes. Such an inhibition， however， could not be detected in the one-stage 
method. 
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DISCUSSION 
In this study， we confirmed the existence of two different types of agglutinins specific for 
BrRBCs in normal sera， showing that their presence is responsible for NS-agglutination in Br 
methods. Biochemical and immunological studies revealed that one (NSA-BrRBC-1) is 
specific for RBCs mildly treated with Br (LBrRBC) and is IgM type and the other (NSA-
BrRBC-II) specific for RBCs drastically treated with Br (HBrRBC) and is IgG. 
Although NSA-BrRBC-I was detected in human blood at a high incidence (99.9 %)， this 
agglutinin does not usually affect the screening and detection of blood group antibodies or the 
crossmatching tests， because the condition of RBC treatment by Br in conventional tests is not 
so drastic as to induce the agglutinability by NSA -BrRBC-I. On the other hand， the presence 
of NSA-Br RBC-1 in the sera of some donors or patients， at a low incidence (2.3 %)， is largely 
responsible for NS-agglutination encountered in routine works. In fact， we observed that NS 
agglutination detected by both two-stage and one-stage Br-methods was abolished by the 
preincubation of sera with BrRBC possessing the ability to be agglutinated by NSA-BrRBC-
1. Therefore we intended to analyze the mechanism of NS-agglutination by NSA-BrRBC-1 
in more detail and tried to identify and characterize the target protein(s) of NSA-BrRBC-1 . 
It is noted that NSA -Br RBC-1 reacted specifically with the binding site unmasked by the 
sensitive arid specific cleavage of RBC surface protein by Br. Thus the binding sites on RBC 
surface could be disclosed by a very mild Br-treatment even at the concentration of 0.0025 % 
(approximately equivalent to 4.5 U Iml of proteinase activity) for 5 seconds in spite of broad 
substrate specificity of Br (Table 1). M and N antigens on the RBC surface stil remained 
intact by such a mild treatment. The appearance of the binding sites is quite specific for Br 
because other proteinases of broad substratespecificity could not induce the agglutination with 
NSA-BrRBC-1 (Table 3). In addition， the exposed binding sites are destroyed with Br at 
higher concentrations or for longer incubation time， the condition which induces the agglutina田
tion with NSA-BrRBC-I. Therefore， the mechanism of Br action to disclose NSA-BrRBC 
1 binding sites seems to be quite different from that to enhance reactivity of certain well 
known antibodies with their antigens， such as Rh system. In those laUer cases， Br is not a 
specifi 
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Cdata not shown). 
We partially purified proteinCs) CNSA-BrRBC-1 -RP) from BrRBC membrane which is the 
target of NSA-BrRBC-1. NSA-BrRBC-1 -RP is thought to be a protein not intact but 
modified by Br-treatment， because the agglutinability of NSA-BrRBC-1 was not inhibited by 
the extract from intact RBC membrane or any fractions from this extract obtained by gel 
filtration. These results are consistent with the previous assumption that Br-treatment directly 
exposes the binding site of NSA-BrRBC-1 on RBC surfaces. The outer membrane domain of 
this RP carrying this binding site is accessible to Pa and Fi because RBCs treated with these 
proteinases before and after Br-treatment were not agglutinated by NSA-BrRBC-1 CTable 
3). 
The molecular size of NSA-BrRBC-1 -RP is assumed to be large， because the Western 
blotting of NSA-BrRBC-1 -RP following electrophoresis by SDS-PAGE in the reduced condi-
tion showed four bands of molecular weights between 26，000 and 160，000 dalton. These bands 
could be observed only when， from the biotinylated partially purified RP preparation， the 
biotinylated RP was concentrated by an immunoprecipitation with NSA-BrRBC-1 ， subjected 
to Western blotting and detected with streptavidin biotinylated HRP complex by use of the 
highly sensitive chemiluminescent staining method Cable to detect less than 1 pg of antigen). 
When the partially purified RP was analyzed by the conventional Western blotting technique， 
no immuno blots specific for NSA-BrRBC-1 could be detected even by the use of the 
chemiluminescent detection method. The partially purified RP fraction， though not verypure 
in SDS-PAGE analysis， showed a very high inhibitory activity against NSA-BrRBC-1 agg-
lutinability Cabove 50，000 fold/mg protein). These results suggest that the amount of this RP 
exposed on RBC is relatively small and that the density is much less than that of RBC 
membrane proteins usually detected in SDS-PAGE ClO'-106 / cel). It is obvious that this RP 
protein is not derived from GPA because no bands were detected with anti-GPAs in the 
Western blotting analysis， though this fact was also expected from the other observations as 
described above. 
Partially purified NSA-BrRBC-1 -RP is expected to be useful for the inhibition of NS-
agglutination in routine works. In fact， the addition of this RP to serum with different NSA 
BrRBC-1 activities was effective for suppressing NS-agglutination in two-st 
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